FY2030 EPS Estimates for enGene Decreased by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN) – Research analysts at Leerink Partnrs dropped their FY2030 EPS estimates for enGene in a research note issued to investors on Thursday, November 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of $1.19 per share for the year, down from their prior forecast of $1.42. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06).

Several other equities research analysts have also recently commented on ENGN. Oppenheimer reissued an “outperform” rating and set a $33.00 target price (up previously from $30.00) on shares of enGene in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Morgan Stanley upped their price objective on enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, November 12th. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a report on Wednesday. Finally, Raymond James Financial upgraded shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price target on the stock in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, enGene currently has a consensus rating of “Moderate Buy” and an average price target of $22.38.

enGene Trading Up 1.2%

Shares of NASDAQ:ENGN opened at $8.53 on Monday. The company has a 50 day moving average of $7.34 and a 200-day moving average of $5.02. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The firm has a market cap of $436.65 million, a P/E ratio of -4.49 and a beta of -0.27. enGene has a twelve month low of $2.65 and a twelve month high of $11.14.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC acquired a new position in shares of enGene in the 2nd quarter valued at $280,000. Adage Capital Partners GP L.L.C. raised its holdings in enGene by 2.7% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after buying an additional 41,874 shares during the period. ADAR1 Capital Management LLC purchased a new stake in enGene during the first quarter valued at about $107,000. Paloma Partners Management Co acquired a new position in shares of enGene in the second quarter worth about $38,000. Finally, Cresset Asset Management LLC purchased a new position in shares of enGene in the second quarter worth approximately $36,000. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.